Aurra | Health News Aggregator

Merck continues to wade deeper into the prescription sleep aid category. The company said Monday that it will file a New Drug Application with the FDA this year for its therapy.

Pfizer named Paul Levesque chief marketing officer for its US primary care business.

The U.S. Solicitor General has filed an amicus brief siding with the pharmaceutical sales representatives in their overtime case against GlaxoSmithKline.

A report by outsourcing firm Challenger, Gray & Christmas showed the pharmaceutical industry ranked third among the highest-layoff industries in January 2012.

Amgen wants to extend use of bone cancer drug Xgeva (denosumab) into the prevention setting, but analysts, not to mention the FDA's own advisors, are not optimistic about its chances.

Amylin said Tuesday that quarterly sales fell 5.3% to $165 million for the period ended December 31 as Byetta sales declined.

Weary of FDA foot-dragging on digital and social media guidance for pharmas, a group of 60-some industry digerati have put together guidelines of their own.

Vaccinating boys between the ages of 11 and 12 against human papillomavirus, or HPV, could become a new part of pre-adolescence if a new recommendation by the Advisory Committee on Immunization Practices takes hold with parents and physicians.

Cowed by a fierce and lighting-quick backlash fueled by angry Tweets and Facebook posts, The Susan G. Komen for the Cure Foundation is backpedaling, but is it too late to reverse the reputation damage?

Allergan removed records from its website that had detailed payments made to doctors from the middle of 2010 through first-half 2011.

Jobson Medical Information Holdings filed for chapter 11 bankruptcy in New York Thursday, the company said, part of an effort to amend and extend its credit and strengthen its balance sheet.

Merck said Thursday its ownership of the global marketplace for DPP-IV diabetes drugs helped it close out the quarter with $12.3 billion in sales, and $48 billion in sales for the year. The two drugs behind the boost were Januvia, which saw a 42% bump in fourth quarter sales, and Janumet, which saw sales jump 34% for the quarter.

AstraZeneca confirmed rumors of another round of deep cuts, announcing that it will eliminate 7,300 positions throughout the company.

The Healthcare Businesswomen's Association named Ernst & Young global pharma lead Carolyn Buck Luce, calling her "a dedicated leader promoting women's advancement in healthcare."

Procter & Gamble is looking to lower its promotion costs by leaning more on digital media, Chairman and CEO Bob McDonald told analysts in an earnings call.

J&J is pushing back hard against a Wall Street Journal article suggesting that a pair of retirements and a promotion are part of a corporate shakeup of its recall-plagued McNeil Consumer Healthcare division.

An online protest, which had more than 2,500 supporters as of Wednesday morning, has pulled the scientific publishing industry into a fight between the publishers and the published.

Fred Wilkinson's "second tour of duty" at Watson includes global expansion, R&D investing and launching branded and generic products

Pharma firms are partnering with managed care companies to find drug evidence and improve outcomes. Can this strategy provide the proof payers demand before giving products preferential treatment?

The Medical Advertising Hall of Fame's three new members have had exceptional lives and careers. We look back at their achievements